PMID- 15126069
OWN - NLM
STAT- MEDLINE
DCOM- 20040604
LR  - 20131121
IS  - 0041-008X (Print)
IS  - 0041-008X (Linking)
VI  - 197
IP  - 1
DP  - 2004 May 15
TI  - Divergent immunological responses following glutaraldehyde exposure.
PG  - 1-8
AB  - Although Glutaraldehyde (Glut) has been demonstrated to be a moderate contact 
      sensitizer, numerous cases of occupational asthma related to Glut exposure have 
      been reported. The purpose of these studies was to examine the dose-response 
      relationship between Glut exposure and the development of T cell-mediated vs. 
      IgE- mediated responses. Initial evaluation of the sensitization potential was 
      conducted using the local lymph node assay (LLNA) at concentrations ranging from 
      0.75% to 2.5%. A concentration-dependent increase in lymphocyte proliferation was 
      observed with EC3 values of 0.072% and 0.089% in CBA and BALB/c mice, 
      respectively. The mouse ear swelling test (MEST) was used to evaluate the 
      potential for Glut to elicit IgE (1/2 h post challenge) and contact 
      hypersensitivity (24 and 48 h post challenge) responses. An immediate response 
      was observed in animals induced and challenged with 2.5% Glut, whereas animals 
      induced with 0.1% or 0.75% and challenged with 2.5% exhibited a delayed response 
      48 h post challenge. IgE-inducing potential was evaluated by phenotypic analysis 
      of draining lymph node cells and measurement of total serum IgE levels. Only the 
      2.5% exposed group demonstrated a significant increase (P < 0.01) in the 
      percentage of IgE(+)B220(+) cells and serum IgE. Following 3 days of dermal 
      exposure, a significant increase in IL-4 mRNA in the draining lymph nodes was 
      observed only in the 2.5% exposed group. These results indicate that the 
      development of an immediate vs. a delayed hypersensitivity response following 
      dermal exposure to Glut is at least in part mediated by the exposure 
      concentration.
FAU - Azadi, Shahla
AU  - Azadi S
AD  - National Institute for Occupational Safety and Health, Morgantown, WV 26505, USA. 
      sazadi@cdc.gov
FAU - Klink, Kimberly J
AU  - Klink KJ
FAU - Meade, B Jean
AU  - Meade BJ
LA  - eng
GR  - Y1-ES-0001-02/ES/NIEHS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Toxicol Appl Pharmacol
JT  - Toxicology and applied pharmacology
JID - 0416575
RN  - 0 (Cytokines)
RN  - 0 (RNA, Messenger)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 82115-62-6 (Interferon-gamma)
RN  - T3C89M417N (Glutaral)
SB  - IM
MH  - Animals
MH  - Cell Division/drug effects
MH  - Cytokines/biosynthesis
MH  - Dermatitis, Contact/*immunology
MH  - Dose-Response Relationship, Drug
MH  - Ear, External/pathology
MH  - Edema/pathology
MH  - Female
MH  - Glutaral/*toxicity
MH  - Immunoglobulin E/*immunology
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-4/biosynthesis
MH  - Local Lymph Node Assay
MH  - Lymph Nodes/drug effects/immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred CBA
MH  - Phenotype
MH  - RNA, Messenger/biosynthesis
MH  - T-Lymphocytes/*drug effects/*immunology
EDAT- 2004/05/06 05:00
MHDA- 2004/06/05 05:00
CRDT- 2004/05/06 05:00
PHST- 2003/12/10 00:00 [received]
PHST- 2004/01/14 00:00 [accepted]
PHST- 2004/05/06 05:00 [pubmed]
PHST- 2004/06/05 05:00 [medline]
PHST- 2004/05/06 05:00 [entrez]
AID - S0041008X04000407 [pii]
AID - 10.1016/j.taap.2004.01.017 [doi]
PST - ppublish
SO  - Toxicol Appl Pharmacol. 2004 May 15;197(1):1-8. doi: 10.1016/j.taap.2004.01.017.